Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI in Combination With Anti-PD-1 Antibody in TKI-responded MSS/pMMR Metastatic Colorectal Adenocarcinoma
NCT04483219Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Jul 2020
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, fruquintinib, regorafenib in colorectal adenocarcinoma, sponsored by China Medical University. Status: unknown.
02
Drugs
toripalimabfruquintinibregorafenib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT04483219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483219.